A prospective feasibility study of cord blood transplant using once daily intravenous busulfan and fludarabine plus melphalan as conditioning regimen

A prospective feasibility study of cord blood transplant using once daily intravenous busulfan and fludarabine plus melphalan as conditioning regimen - FluBuOnceDaily plus Mel for CBT

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000030308

Enrollment

Registered

2017-12-09

Start date

2017-12-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematological malignancy

Interventions

once daily intravenous busulfan in combination with melphalan in the setting of CBT

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Age 18 years or older less than 70 years (2) patients with a hematological malignancy who are eligible for CBT (3) patients who will receive CBT (4) ECOG PS 0 or 1 (5) patients with consent to this study

Exclusion criteria

Exclusion criteria: (1) patients with organ dysfunction (lung, renal, liver, heart) (2) patients who are expected not to survive 100 days or longer (3) patients with another active cancer (4) pregnant or breast-feeding (5) patients with mental disorder (6) the physician consider inappropriate for this study

Design outcomes

Primary

Measure	Time frame
Engraftment rate	—

Secondary

Measure	Time frame
(1) non-relapse mortality rate at 100 days after CBT (2) SOS rate at 100 days after CBT (3) 1-year overall survival and relapse rates	—

Countries

Japan

Contacts

Public ContactShigeo Fuji

Osaka International Cancer Institute Department of Hematology

fujishige1231@gmail.com06-6945-1181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026